Rare diseases are defined in the US as conditions that affect fewer than 1 in 1500 people. By their very definition of serving a relatively small population of people, the cost of developing brand new drugs for this audience (or orphan drugs) can be prohibitively expensive.
During this 45-minute webinar, Michael Hughes, Head of Data Science brings his unique industry and technical experience as a bioinformatician and developer to explore:
Just released by the Copyright Clearance Center, a semantic search solution applied to full-text articlesRead
In this blog we cover how to look potentially reduce the cost of and speed up the repurposing pipeline.Read
Get in touch with us to find out how we can transform your data
© Copyright © 2024 Elsevier Ltd., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.